已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Current practices and trends of breast-conserving surgery in China: A nationwide cross-sectional survey

医学 乳腺癌 乳房切除术 家庭医学 保乳手术 委派 答辩人 社会经济地位 分级(工程) 普通外科 中国 梅德林 乳房外科 标准化 肿瘤整形外科 妇科 癌症 发达国家 审计 宫颈癌 替代医学 最佳实践 模式 前哨淋巴结 外科 外科肿瘤学 计算机辅助网络访谈
作者
Hao Zhu,Cuizhi Geng,Xinyuan Xia,Zhibo Shao,Qi Zhang,Xuliren Wang,Shuang Hao,Benlong Yang,JiaJian Chen,Z. Shao,Bingqiu Xiu,Jiong Wu
出处
期刊:Chinese Medical Journal [Lippincott Williams & Wilkins]
卷期号:139 (22): 3465-3467 被引量:2
标识
DOI:10.1097/cm9.0000000000003929
摘要

Breast cancer is the most frequently diagnosed malignancy in the Chinese female population.[1] Breast-conserving surgery (BCS) has long been established as the cornerstone of early-stage breast cancer treatment, with numerous clinical trials confirming its oncologic equivalence to mastectomy in appropriately selected patients. In developed countries, BCS rates among patients with early-stage breast cancer typically range from 60% to 80%.[2] However, its adoption in China remains relatively low; a national cross-sectional study conducted in 2017 reported an overall BCS rate of only 22%.[3] Therefore, understanding the factors influencing BCS adoption, including institutional and socioeconomic elements, is crucial for improving the standardization of care and enhancing the acceptance of BCS across clinical settings in China. Through a questionnaire survey conducted across 215 hospitals in Chinese Mainland, this study aimed to assess current practices and trends in BCS, identify factors influencing its adoption, and explore the use of oncoplastic techniques and margin assessment strategies. By comparing with the 2017 survey from the same series,[3] the study aims to guide future initiatives to enhance the safety, accessibility, and effectiveness of BCS in China. A standardized questionnaire [Supplementary Material, https://links.lww.com/CM9/C713] was developed to assess current surgical practices for breast cancer treatment in hospitals accredited by the Chinese Anti-Cancer Association’s Committee of Breast Cancer Society (CACA-CBCS) and the Chinese Society of Breast Surgeons (CSBS). It consisted of seven sections: respondent and hospital practices, axillary lymph node surgery, BCS, breast reconstruction, endoscopy-assisted breast surgery, revision procedures, and surgical management of lymphedema. The questions in the BCS section remained largely consistent with the 2017 questionnaire, ensuring comparability between the two surveys. This study did not include specific patient data, human or animal samples. Data are collected from hospital statistics and doctors’ opinions. The Board of Ethical Committee of Fudan University Shanghai Cancer Center (FUSCC) waived the requirement of ethical approval for this research. In the 2017 survey, the standardized questionnaire was distributed to hospitals nationwide that had performed at least 200 breast cancer surgeries. A sampling strategy was employed to enhance the diversity of the participating hospitals, considering their geographic distribution and annual surgical volume. Hospitals were selected across different provinces and surgical volume ranges. This selection method resulted in the inclusion of 110 centers in 2017. In line with the 2017 survey, hospitals were selected based on a similar sampling strategy in 2022. A total of 215 centers were selected. To ensure data reliability, the CACA-CBCS and CSBS notified the directors of these centers, and each department assigned a specialist to complete the questionnaire. By 17 March 2024, 198 centers fully responded to the survey and were included in the analysis. Fully completed questionnaires that were free of logical errors were considered valid. Categorical data were presented as counts and percentages, while continuous data were summarized as medians with interquartile ranges (IQRs) due to their non-normal distribution. For cross-sectional analysis of the 2022 survey data, the Kruskal–Wallis rank sum test was used to compare continuous variables across multiple groups. To evaluate differences between the 2022 and 2017 surveys, the Mann–Whitney U test was applied for continuous variables, and the Chi-squared test was applied for categorical variables. Univariable and multivariable linear regression models were used to explored the factors associated with re-excision rates. All analyses were conducted using SPSS 27.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 9.0 (GraphPad Software, San Diego, CA, USA). A value of P less than 0.05 was considered statistically significant. Of the 215 hospitals surveyed in 2022, 198 provided complete responses on BCS, resulting in a 92.1% (198/215) response rate. The surveyed hospitals collectively reported 123,907 breast cancer surgeries, with BCS accounting for 26.6% (32,983/123,907), an increase from 21.9% in 2017. Additionally, the institutional median BCS rate increased from 15.0% (IQR: 15.0–25.0%) in 2017 to 22.0% (IQR: 18.0–30.0%) (P <0.001) in 2022, indicating a notable advancement in BCS adoption. Analysis by cancer stage showed increased BCS rates across all stages, with a statistically significant increase for stage I cancer (P = 0.010), but not for stages 0 (P = 0.780), II (P = 0.122), or III (P = 0.121) [Supplementary Figure 1A, https://links.lww.com/CM9/C713]. Despite this progress, BCS rates varied substantially across institutions [Supplementary Figure 1B, https://links.lww.com/CM9/C713]. The presence of qualified plastic surgeons was associated with higher BCS rates (median 25.0% vs. 20.0%, P = 0.034) [Supplementary Table 1, https://links.lww.com/CM9/C713]. Although not statistically significant, hospitals with a greater breast surgical volume (median 40.0% vs. 20.0%, P = 0.243) and more breast surgeons (median 35.0% vs. 25.0%, P = 0.211) also had a higher BCS rate. However, factors such as hospital region and high per capita GDP showed no association with BCS rates. The survey revealed a median BCS rate of 20.0% (IQR: 10.0–30.0%) following neoadjuvant therapy in 2022, an increase from 5% (IQR: 5–15%) in 2017. In 22% of the hospitals surveyed, BCS was performed in more than 30.0% of the patients who underwent neoadjuvant therapy [Supplementary Figure 1C, https://links.lww.com/CM9/C713], whereas only 15% of the hospitals achieved this in 2017. None of those above key factors were significantly associated with the BCS rate following neoadjuvant therapy [Supplementary Table 1, https://links.lww.com/CM9/C713]. We then examined the methods used for evaluating surgical margins in BCS across different institutions. Tangential shaved margins remained the predominant choice for pathological sampling (66.2%, 131/198) [Supplementary Figure 2A, https://links.lww.com/CM9/C713]. However, the adoption of perpendicular inked margins had increased compared to 2017 (33.8% vs. 25.5%, χ2 = 2.33, P = 0.127). Additionally, approximately 50% of the surveyed hospitals regularly performed margin staining (49.4% in 2022 vs. 24.5% in 2017, χ2 = 18.25, P <0.001) and more than half routinely performed cavity shaving (56.1% in 2022 vs. 31.8% in 2017, χ2 = 16.67, P <0.001) [Supplementary Figures 2B and C, https://links.lww.com/CM9/C713]. For the newly added aspect of pathological evaluation methods, nearly all hospitals favored intraoperative frozen section analysis (92.9%, 184/198) over postoperative paraffin section analysis [Supplementary Figure 2D, https://links.lww.com/CM9/C713]. The median re-excision rate reported in this survey was 6.0% (IQR: 3.0–15.0%), which was considerably higher than the 2.5% (IQR: 2.5–8.0%) reported in 2017. Half (99/198) of the hospitals reported a re-excision rate of 5% or less [Supplementary Figure 2E, https://links.lww.com/CM9/C713]. The implementation of contralateral symmetry procedures was associated with a notably reduced risk of re-excision (odds ratio [OR] = 0.491, 95% CI: 0.264–0.912, P = 0.024) [Supplementary Table 2, https://links.lww.com/CM9/C713]. Conversely, BCS following neoadjuvant chemotherapy was modestly but significantly linked to a higher re-excision rate (OR = 1.029, 95% CI: 1.011–1.048, P = 0.002). In the multivariate model adjusted for variables with clinical relevance (routine margin staining and use of cavity shave margins) and those with statistical significance in univariable analysis (contralateral symmetry procedures and neoadjuvant chemotherapy use), neoadjuvant chemotherapy remained an independent predictor of increased re-excision rates (OR = 1.030, 95% CI: 1.008–1.053, P = 0.007). The use of oncoplastic techniques in BCS showed no significant change between 2017 and 2022 (median 30.0% vs. 30.5%, P = 0.164). However, adoption rates varied widely among hospitals. While 25.8% of hospitals performed oncoplastic surgery (OPS) in >50% of BCS cases, over one-fourth of hospitals (28.8%, 57/198) reported rates of 10% or lower [Supplementary Figure 3A, https://links.lww.com/CM9/C713]. Higher OPS rates were correlated with increased surgical volume (median 40.0% vs. 20.0%, P <0.001), a greater number of breast surgeons (median 35.0% vs. 25.0%, P = 0.035), and routine implementation of contralateral symmetry procedures (median 35.0% vs. 20.0%, P = 0.001) [Supplementary Table 1, https://links.lww.com/CM9/C713]. Among the different oncoplastic techniques used in BCS [Supplementary Figure 3B, C, https://links.lww.com/CM9/C713], the volume displacement technique was considerably more commonly used than the volume replacement technique (median, 70.0% vs. 30.0%, P <0.001), which is consistent with that observed in 2017. Regarding the factors potentially associated with the choice of oncoplastic techniques, statistical analysis revealed that the use of contralateral symmetry procedures was correlated with a higher rate of volume displacement techniques (median 70.0% vs. 51.0%, P = 0.003). This study presents a comprehensive analysis of current BCS practices in China, highlighting the increasing but relatively low rates of BCS. A major contributing factor to this disparity may be the low rate of early-stage breast cancer diagnosis, which contributes to a higher proportion of mastectomies. A recent global meta-analysis reported that only about 60% of breast cancers in China are diagnosed early for stages I and II, compared to approximately 90% in the United States.[4] Cultural conservatism also plays a role, as many Chinese patients are reluctant to choose BCS due to concerns of local recurrence. Addressing these challenges through improved patient education and stronger doctor–patient communication may help increase the acceptance and adoption of BCS. Neoadjuvant therapy for early-stage breast cancer can increase the feasibility of BCS. In our cohort, BCS rates following neoadjuvant therapy strongly correlated with overall BCS rates. Multiple studies have reported that, compared to patients undergoing direct surgery, those receiving neoadjuvant therapy may have a slightly higher risk of local recurrence; however, this does not appear to negatively impact long-term patient survival.[5] Therefore, optimizing patient selection and evaluation and refining tumor bed localization are critical during the perioperative period for patients undergoing neoadjuvant therapy. Effective pathological assessment of surgical margins is essential to the safety and success of BCS. Since 2017, our study has reported increased adoption of perpendicular inked margins, routine use of margin staining, and cavity shaving. International guidelines consistently recommend the “no ink on tumor” standard to define negative margins. However, a recent meta-analysis reported that closer margins (less than 2 mm) were associated with a higher risk of local recurrence and distant metastasis.[6] In this context, the adoption of perpendicular inked margins should be emphasized, as it allows for an accurate measurement of the distance between the lesion and the surgical margin. Our study found a median re-excision rate of 6.0%, considerably lower than the 15–20% observed in developed countries. This difference may reflect the use of stricter criteria and broader excision scope in China. Univariate and multivariate logistic regression analyses revealed neoadjuvant therapy as a risk factor for re-excision, possibly due to non-concentric tumor shrinkage after neoadjuvant therapy. Therefore, reliable imaging examinations to evaluate tumor regression patterns and the extent of response to neoadjuvant therapy may help reduce re-excision rates. Oncoplastic BCS combines oncologic surgical techniques with plastic surgery methods to restore the breast shape while ensuring oncological safety. Our survey revealed that the overall adoption rate of OPS in 2022 remained largely unchanged from 2017, with substantial variability across hospitals. OPS can be categorized into two main types: volume displacement and volume replacement. Our study indicated that volume displacement remained the predominant oncoplastic approach in China, although the use of volume replacement techniques had increased since 2017. The prevalence of volume displacement techniques may be due to their relative ease of implementation, particularly in centers with limited oncoplastic resources. Nonetheless, the choice between these techniques should be individualized, as both offer distinct advantages depending on the clinical scenario. This study has certain limitations. First, its questionnaire-based design introduces potential response bias, which may affect the accuracy and generalizability of the findings. Second, the cross-sectional nature of the study precludes the establishment of causal relationships between hospital characteristics and surgical outcomes. Third, the absence of patient-level data limits evaluation of the safety and effectiveness of the reported practices. Future research employing longitudinal, patient-based cohorts is needed to offer a more comprehensive understanding. Despite these limitations, this study offers a comprehensive analysis of BCS practices in China, highlighting an overall increase in BCS adoption, particularly following neoadjuvant therapy. While the evaluation of pathological margins is becoming more standardized, interhospital variability persists. OPS rates showed minimal change over 5 years, with oncoplastic resource allocation potentially limiting its development. Further research is needed to assess the long-term impact of current surgical practices and optimize patient outcomes. Acknowledgment We acknowledge the staff of the CBCS and CSBS working groups for their support in participant recruitment and data collection. Funding This study was supported by the Shanghai Academic Research Leader Program (No. LJRC2202) and the Science and Technology Commission of Shanghai Municipality (No. KW2234). Conflicts of interest None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
chen发布了新的文献求助10
刚刚
成为一只会科研的猫完成签到 ,获得积分10
刚刚
桐桐的应助被学术大拿采纳,获得10
2秒前
2秒前
2秒前
整齐志泽完成签到 ,获得积分10
2秒前
3秒前
4秒前
5秒前
7秒前
pure完成签到 ,获得积分10
7秒前
酷波er的应助被zhaoruoqi0425采纳,获得10
7秒前
欣慰的海发布了新的文献求助10
7秒前
秋风的应助被lnvvl采纳,获得20
8秒前
Mjj发布了新的文献求助10
8秒前
田様的应助被WilliamTT采纳,获得10
8秒前
Rina发布了新的文献求助10
8秒前
生动的孤容完成签到 ,获得积分10
8秒前
吉伊完成签到 ,获得积分10
10秒前
11秒前
11秒前
愉快的翅膀完成签到 ,获得积分10
11秒前
11秒前
小明同学发布了新的文献求助10
12秒前
dazhuang发布了新的文献求助30
13秒前
13秒前
14秒前
doranlou完成签到 ,获得积分10
14秒前
柯慕玉泽完成签到 ,获得积分10
14秒前
科研通AI6.2的应助被nuodei采纳,获得10
16秒前
玻璃弹珠发布了新的文献求助10
16秒前
Goodies发布了新的文献求助10
16秒前
16秒前
YY完成签到,获得积分10
16秒前
学术大拿发布了新的文献求助10
17秒前
Mlody完成签到,获得积分10
18秒前
初景发布了新的文献求助10
18秒前
19秒前
gyq发布了新的文献求助10
19秒前
酷波er的应助被李小雨采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194542
求助须知:如何正确求助?哪些是违规求助? 9580381
关于积分的说明 21870692
捐赠科研通 7794154
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2560995
邀请新用户注册赠送积分活动 2484393